Amit Tirosh

Specialization: Endocrinologist
26 years of experience
Speaks:
English, Hebrew
Online consultations: available
Workplace: Israel, Ramat Gan, Sheba Medical Center
Heads a NET service; international VHL expert panelist and contributor to clinical guidelines.
Dr. Amit Tirosh is the Head of the Neuroendocrine Tumors (NET) Service at Sheba Medical Center. He is an international authority on von Hippel–Lindau (VHL) disease and hereditary tumor syndromes. Dr. Tirosh contributed to global clinical guidelines for VHL management. He also leads the Endocrine Oncology Bioinformatics Lab at Sheba.
- Contributor to the international expert panel on VHL management guidelines.
- Authored over 40 peer-reviewed papers in journals like JAMA and Gastroentrology.
- Maintains research affiliations with the NIH and the Weizmann Institute.
- Performs specialized NET treatments, including Lutetium-177 therapy and PRRT.

Explore package deals with Dr. Amit Tirosh

Select Procedure

PNET (Pancreatic neuroendocrine tumor) Advanced Diagnostics Program at Sheba Medical Center (Top 10 Worldwide)

$5,000

per package

The package includes a standard range of medical services offered by the clinic and additional benefits like accommodation, transfer, etc.

Online consultation with Amit Tirosh

Convenient and easy

100% secure and confidential

$650

How are we doing?

1 of 3

Information about this doctor is full and clear

Strongly disagree

Strongly agree

Qualifications

Prof. Amit Tirosh is a endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He is an authority on von Hippel–Lindau (VHL) disease and hereditary endocrine syndromes. Prof. Tirosh contributed to the global clinical guidelines for managing VHL patients.

Specialization and Oncology Services

Prof. Tirosh treats neuroendocrine tumors (NETs). He specializes in hereditary syndromes, including MEN1 and VHL disease. He serves as the primary contact for the multidisciplinary VHL clinic at Sheba. The specialist offers treatments such as Peptide Receptor Radionuclide Therapy (PRRT).

PRRT is a molecular therapy that delivers radiation directly to cancer cells. The doctor treats a range of conditions, including:

Pancreatic neuroendocrine tumors
Adrenal adenomas
Pancreatic, stomach, and colon cancers
Kidney and testicular cancers
Small intestine cancer

He uses diagnostic tools such as PET-CT with Gallium 68 and whole-body MRI. His therapeutic approach includes Lutetium-177 therapy and targeted biological treatments.

Academic and Research Leadership

The specialist leads the Endocrine Oncology Bioinformatics Lab. He investigates new data-driven methods to treat endocrine cancers. Dr. Tirosh collaborates with the Weizmann Institute of Science and teams in Italy and Germany. Additionally, he lectures at Tel Aviv University’s Faculty of Medicine.

Professional History

Head of Neuroendocrine Tumors Service – Sheba Medical Center
Affiliated Researcher – National Institutes of Health (NIH), USA
Faculty Member – Tel Aviv University
Endocrinology Fellow – Rabin Medical Center
Internal Medicine Resident – Assaf HaRofeh Medical Center

Education and Training

Doctor of Medicine – Hadassah Medical School, Hebrew University of Jerusalem
Specialty Training – Internal Medicine, Assaf HaRofeh Medical Center
Fellowship – Endocrinology, Rabin Medical Center
Advanced Training – Neuroendocrine Tumors and Genetics, National Institutes of Health (USA)
Board Certification – Endocrinology

Publications and Memberships

Prof. Tirosh has authored over 40 peer-reviewed papers. His research appears in journals such as JAMA, Gastroenterology, Radiology, and Oncology. Notable works include studies on VHL-associated tumors and radioguided surgery for NETs.

He is a member of several professional organizations:

European Neuroendocrine Tumor Society
American Endocrine Society
Israeli Society of Endocrinology